通过NMT2准N-Myristoylation可以预防心脏缩和心脏衰竭
Yusuke Tomita1, Fumiya Anzai1, Tomofumi Misaka1,2
1Department of Cardiovascular Medicine, Fukushima Medical University, Fukushima, Japan.
JACC. Basic to translational science
|December 14, 2023
概括
N-myristoylation 增强了蛋白质的多样性. 准心脏N-myristoyltransferase 2 (NMT2) 可能通过调节心脏缩和重塑来预防心力衰竭.
科学领域:
- 生物化学 生物化学
- 分子生物学分子生物学
- 心血管研究研究心血管研究
背景情况:
- 蛋白质多样性对于细胞功能至关重要.
- N-myristoylation,即对N-终端甘氨酸添加米里斯酸,是关键的翻译后修改.
- 心脏功能障碍和心力衰竭涉及复杂的分子变化.
研究的目的:
- 调查心脏N-myristoyltransferase 2 (NMT2) 在压力过载引起的心力衰竭中的作用.
- 在心脏肌细胞中识别N-myristoylation的基质.
- 探索NMT2作为潜在的治疗心力衰竭的目标.
主要方法:
- 使用心脏压力过载的小鼠模型.
- 使用腺相关病毒9进行NMT2敲击.
- 应用基于化学的定量化学蛋白质学来识别N-myristoylation基质.
- 评估心脏功能,重塑和缩标志物.
主要成果:
- NMT2敲击导致心脏功能障碍恶化,重塑和失败.
- 鉴定标记作为心脏肌细胞中的N-myristoylation基质.
- 通过抑制Ca2+/calmodulin-dependent蛋白激酶II和基因素脱乙酶4激活,以及基因素乙化,MARCKS的N-myristoylation可以预防病理性缩.
- 转移NMT2的基因改善了心脏功能,并减少了心脏衰竭.
结论:
- NMT2在心脏中起着保护性作用,防止压力过载.
- 马克斯N-myristoylation是心脏缩的一个关键调节器.
- 通过NMT2向N-myristoylation是预防心脏重塑和心脏衰竭的有希望的治疗策略.
相关概念视频
01:27Transducer Mechanism: Enzyme-Linked Receptors
2.5K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.5K
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
436
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
436